

# Jeffrey Bradley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11545209/publications.pdf>

Version: 2024-02-01

29  
papers

4,520  
citations

394421

19  
h-index

501196

28  
g-index

29  
all docs

29  
docs citations

29  
times ranked

4411  
citing authors

#	ARTICLE	IF	CITATIONS
1	Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer. JAMA - Journal of the American Medical Association, 2010, 303, 1070.	7.4	2,185
2	Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2004, 59, 78-86.	0.8	534
3	Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiotherapy and Oncology, 2018, 126, 519-526.	0.6	320
4	Non-small-cell Lung Cancer With Brain Metastasis at Presentation. Clinical Lung Cancer, 2018, 19, e373-e379.	2.6	162
5	Treatment of stage I lung cancer in high-risk and inoperable patients: Comparison of prospective clinical trials using stereotactic body radiotherapy (RTOG 0236), sublobar resection (ACOSOG Z4032), and radiofrequency ablation (ACOSOG Z4033). Journal of Thoracic and Cardiovascular Surgery, 2013, 145, 692-699.	0.8	153
6	No Clinically Significant Changes in Pulmonary Function Following Stereotactic Body Radiation Therapy for Early- Stage Peripheral Non-Small Cell Lung Cancer: An Analysis of RTOG 0236. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1092-1099.	0.8	145
7	Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1106-1113.	0.8	139
8	Simulated Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Disease of the Abdomen and Central Thorax: Characterization of Potential Advantages. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1078-1086.	0.8	113
9	A Phase II Comparative Study of Gross Tumor Volume Definition With or Without PET/CT Fusion in Dosimetric Planning for Non-small-Cell Lung Cancer (NSCLC): Primary Analysis of Radiation Therapy Oncology Group (RTOG) 0515. International Journal of Radiation Oncology Biology Physics, 2012, 82, 435-441.e1.	0.8	99
10	Analysis of first recurrence and survival in patients with stage I non-small cell lung cancer treated with surgical resection or stereotactic radiation therapy. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 1183-1192.e10.	0.8	91
11	Definitive radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. Practical Radiation Oncology, 2015, 5, 141-148.	2.1	79
12	Adjuvant radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. Practical Radiation Oncology, 2015, 5, 149-155.	2.1	78
13	Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC. Journal of Thoracic Oncology, 2016, 11, 1729-1735.	1.1	74
14	A Review of Radiation Dose Escalation Trials for Non-Small Cell Lung Cancer Within the Radiation Therapy Oncology Group. Seminars in Oncology, 2005, 32, 111-113.	2.2	71
15	Radiation esophagitis: Predictive factors and preventive strategies. Seminars in Radiation Oncology, 2004, 14, 280-286.	2.2	52
16	Radiographic Response and Clinical Toxicity Following SBRT for Stage I Lung Cancer. Journal of Thoracic Oncology, 2007, 2, S118-S124.	1.1	50
17	Combining stereotactic body radiation therapy with immunotherapy: current data and future directions. Translational Lung Cancer Research, 2018, 8, 107-115.	2.8	40
18	Radiation Pneumonitis and Esophagitis in Thoracic Irradiation. Cancer Treatment and Research, 2008, 128, 43-64.	0.5	36

#	ARTICLE	IF	CITATIONS
19	The world's first single-room proton therapy facility: Two-year experience. <i>Practical Radiation Oncology</i> , 2017, 7, e71-e76.	2.1	21
20	A Phase I Study of Temsirolimus and Thoracic Radiation in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 119-123.	2.6	20
21	Task Group 174 Report: Utilization of [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography ( <sup>18</sup> F) FDG PET/CT in Radiation Therapy. <i>International Journal of Radiation Oncology</i> , 2010, 78, 177-191.	3.0	15
22	New Territory: Surgical Salvage for Stereotactic Body Radiation Therapy Failures in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1879-1880.	1.1	11
23	Toward adaptive proton therapy guided with a mobile helical CT scanner. <i>Radiotherapy and Oncology</i> , 2018, 129, 479-485.	0.6	11
24	Does Proton Therapy Offer Demonstrable Clinical Advantages for Treating Thoracic Tumors?. <i>Seminars in Radiation Oncology</i> , 2018, 28, 114-124.	2.2	7
25	Clinical prognostic model for older patients with advanced non-small cell lung cancer. <i>Journal of Geriatric Oncology</i> , 2019, 10, 555-559.	1.0	6
26	Delineation of a Cardiac Planning Organ-At-Risk Volume Using Real-Time Magnetic Resonance Imaging for Cardiac Protection in Thoracic and Breast Radiation Therapy. <i>Practical Radiation Oncology</i> , 2019, 9, e298-e306.	2.1	4
27	The Ever-Increasing Number of Trial Eligibility Criteria: Time to Bend the Curve. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1459-1460.	1.1	3
28	Learning From Trials on Radiation Dose in Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 748-750.	0.8	2
29	Current role of PET in oncology: Potentials and challenges in the management of non-small cell lung cancer. , 2008, , .		1